WO2018155995A1 - Composition antibacterienne contenant du sialyllactose en tant que principe actif - Google Patents

Composition antibacterienne contenant du sialyllactose en tant que principe actif Download PDF

Info

Publication number
WO2018155995A1
WO2018155995A1 PCT/KR2018/002390 KR2018002390W WO2018155995A1 WO 2018155995 A1 WO2018155995 A1 WO 2018155995A1 KR 2018002390 W KR2018002390 W KR 2018002390W WO 2018155995 A1 WO2018155995 A1 WO 2018155995A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyaryllactose
composition
antimicrobial
present
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/002390
Other languages
English (en)
Korean (ko)
Inventor
김재화
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2018155995A1 publication Critical patent/WO2018155995A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose

Definitions

  • the present invention relates to a composition for antimicrobial activity against Klebsiella pneumoniae , comprising cyaryl lactose as an active ingredient, and specifically, ⁇ 2,3-cyaryllactose or ⁇ 2,6-cyaryllactose. Containing as an active ingredient, it relates to a composition for antimicrobial activity against Krebsciella pneumoniae, a composition for promoting phagocytosis of macrophages to Krebssiella pneumoniae.
  • VRE vancomycin-resistant Enterococcus
  • composition containing ⁇ 2,3-silylactose or ⁇ 2,6-cyaryllactose exhibits high antibacterial activity against Klebsiella pneumoniae .
  • composition containing ⁇ 2,3-silylactose or ⁇ 2,6-silylactose can be usefully used as an antimicrobial composition, thereby completing the present invention.
  • One object of the present invention is to provide an antimicrobial composition against Klebsiella pneumoniae , comprising silyllactose as an active ingredient.
  • Another object of the present invention is to provide an antimicrobial use of sialyllactose against Klebsiella pneumoniae .
  • composition comprising a silyllactose (sialyllactose) for the production of antimicrobial agents, antimicrobial quasi-drugs or antimicrobial food for Klebsiella pneumoniae It is to provide a use.
  • the present invention provides an antimicrobial composition comprising siarylactose as an active ingredient, an antimicrobial composition having an excellent antimicrobial activity against a Krebsella pneumoniae strain, and a composition for promoting phagocytosis of macrophages.
  • 1 is a graph confirming the presence or absence of cytotoxicity of 2,3-cyaryllactose and 2,6-cyaryllactose in THP-1 cells and Raw 264.7 cells.
  • FIG. 2 is a graph showing the expression level of CXCL8 and TNF- ⁇ when THP-1 cells were treated with 2,3-ciarylactose and LPS alone or in combination.
  • FIG. 3 shows a CXCL8 reporter vector (A) prepared using a CXCL8 promoter region including a binding sequence of STAT, AP-1, and NF- ⁇ B and a luciferase expression gene, and 2,3-cyaryllactose in A549 cells.
  • LPS shows the degree of luciferase activity following treatment alone or in combination.
  • Figure 4 shows the process of confirming the phagocytosis promoting ability of 3-cyaryl lactose, Klebsiella pneumoniae bacteria of 2,6-siaryl lactose.
  • FIG. 5 is a graph showing phagocytosis promoting activity of 2,3-silylactose and 2,6-silylactose against Klebsiella pneumoniae . (Vertical axis unit: CFU; horizontal axis unit: time)
  • FIG. 6 confirms whether phagocytosis is promoted against 2,3-silylactose, 2,6-silylactose, Staphylococcus aureus, and Streptococcus pseudopneumonia.
  • Figure 7 confirms the phagocytosis activity of 2,3-cyaryllactose, 2,6-cyaryllactose through endocytosis verification of the TLR4 receptor.
  • One aspect of the present invention for achieving the above object provides a composition for antimicrobial against Klebsiella pneumoniae , containing sialyllactose as an active ingredient.
  • Another embodiment provides the antimicrobial use of sialyllactose against Klebsiella pneumoniae .
  • sialylactose is an oligosaccharide form of sialic acid, and is known as a substance having the formula C 23 H 39 NO 19 and a molecular weight of 633.5511 g / mol.
  • siaryl lactose may be specifically 2,3-silylactose, 3-syaryllactose, 2,6-syaryllactose, 6-syaryllactose, ⁇ 2,3-syaryllactose or ⁇ 2,6-syaryl It may be used in combination with lactose.
  • the 2,3-silaryl lactose or 2,6-silaryllactose is a compound composed of the following Chemical Formula 1 or 2, respectively.
  • the present invention is not particularly limited to the method for obtaining cyaryllactose, and chemically synthesized by a method known in the art, or a commercially available material may be used.
  • the cyaryllactose of the present invention may exist in both solvated and unsolvated forms.
  • the cyaryllactose of the present invention may exist in crystalline or amorphous form, and all such physical forms are included in the scope of the present invention.
  • antibacterial in the present invention means the activity of preventing or treating the infection of the bacteria by inhibiting the growth or proliferation of the bacteria including microorganisms.
  • the siaryl lactose, or a composition comprising the same may be one having an antimicrobial activity against Klebsiella pneumoniae .
  • Klebsiella pneumoniae ( Glebsiella pneumoniae ) is a Gram-negative simple bacillus and corresponds to a pathogen that is present in the intestine, oral cavity of a human.
  • Sepharosemorin antibiotics are known to be effective in the treatment of diseases caused by Krebsiella pneumoniae infection, but the antimicrobial activity of 2,3-cyaryllactose or 2,6-cyaryllactose against Krebssiella pneumoniae Is not known and was first identified by the inventors.
  • the antimicrobial activity of cyaryllactose against Klebsiella pneumoniae was confirmed that silylactose promotes phagocytosis against Klebsiella pneumoniae . (FIGS. 4 and 5), on the other hand it was confirmed that it does not have antibacterial activity against other bacteria. Therefore, it was confirmed that siarylactose had specific antimicrobial activity against Krebs.
  • the siaryl lactose may be to increase the expression amount of chemokine CXCL8 in macrophages.
  • chemokine refers to a basic heparin-binding small molecule protein that acts as a leukocyte inducer, activating, CXC (CXCL), CC (CCL), CX 3 C (CX 3 CL), C ( More than 40 species have been identified, classified into four subclasses of XCL).
  • CXCL CXC
  • CCL CCL
  • CX 3 C CX 3 CL
  • CXCL8 interleukin 8
  • IL8 interleukin 8
  • the siaryl lactose may be to increase the active oxygen content or lysosomal activity in the macrophages.
  • Rh. 8 Ras protein that produces free radicals (ROS) is a macrophage cell. It was confirmed that the phenomenon of gathering to the surface is apparent, the activity of the lysosomes in the macrophages is increased (Fig. 8).
  • the siaryl lactose may be to promote phagocytosis of the macrophages.
  • Yet another aspect of the present invention provides a composition for promoting phagocytosis of macrophages to Klebsiella pneumoniae , which includes sialyllactose as an active ingredient.
  • Phagocytosis in the present invention refers to a phenomenon in which macrophages receive and treat pathogens or foreign bodies invaded from the outside.
  • Another aspect of the present invention for achieving the above object provides a pharmaceutical composition for antimicrobial comprising a siary lactose as an active ingredient.
  • the antimicrobial pharmaceutical composition may be one having an antimicrobial activity against Klebsiella pneumoniae .
  • Another embodiment provides the use of a composition comprising sialyllactose as an active ingredient for the preparation of an antimicrobial agent against Klebsiella pneumoniae .
  • the siaryl lactose, Krebssiella pneumoniae, antibacterial is as described above.
  • composition containing the siarylactose of the present invention as an active ingredient can be usefully used as an antimicrobial pharmaceutical composition for inhibiting the growth of Krebssiella pneumoniae.
  • the pharmaceutical composition of the present invention may also be used as a single agent, and may be prepared and used as a complex preparation further including a pharmaceutical composition known to have a recognized antimicrobial effect.
  • the pharmaceutical composition of the present invention may be formulated in a pharmaceutical unit dosage form by adding a pharmaceutically acceptable carrier, excipient, or diluent.
  • composition comprising a pharmaceutically acceptable carrier in the present invention may be a variety of oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It may have a formulation of.
  • siaryllactose in the composition of the present invention may be included in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the type and severity, age, sex, activity of the drug , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
  • the siaryl lactose in the present invention may be included in 0.001 to 200 ⁇ g / ml, more preferably 0.001 to 100 ⁇ g / ml in the pharmaceutical composition.
  • Another aspect of the present invention for achieving the above object provides an antimicrobial composition for antimicrobial comprising a siary lactose as an active ingredient.
  • Another embodiment provides the use of a composition comprising siallyllactose as an active ingredient for the preparation of an antimicrobial product for antimicrobial against Klebsiella pneumoniae .
  • the siaryl lactose, Krebssiella pneumoniae, antibacterial is as described above.
  • the quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components.
  • a pharmaceutically acceptable carrier, excipients or diluents are not limited so long as they do not impair the effects of the present invention.
  • composition containing the above-mentioned cyaryl lactose of the present invention when using the composition containing the above-mentioned cyaryl lactose of the present invention as an active ingredient, it may further contain one or more active ingredients exhibiting the same or similar functions.
  • known antimicrobial components may be included. Inclusion of additional antimicrobial components may further increase the antimicrobial effect of the compositions of the present invention.
  • the quasi-drug composition may further include an antimicrobial component known in the art.
  • the quasi-drug composition of the present invention may be exemplified by disinfecting detergents, shower foams, ointments, wet tissues, coatings, etc., but is not limited thereto.
  • Formulation methods, dosages, methods of use, components, etc. of the quasi-drugs are well known in the art. Can be appropriately selected from the description of.
  • Another aspect of the present invention for achieving the above object provides a food composition for antimicrobial comprising a siary lactose as an active ingredient.
  • Another embodiment provides the use of a composition comprising siaryllactose as an active ingredient for the production of antimicrobial foods against Klebsiella pneumoniae .
  • the siaryl lactose, Krebssiella pneumoniae, antibacterial is as described above.
  • the food composition of the present invention contains a substance derived from natural products and can be consumed on a daily basis, it can be expected to have a high antimicrobial effect against Krebs.
  • the antimicrobial food composition of the present invention includes pills, powders, granules, acupuncture, tablets, capsules or liquids, and the like, and the foods to which the composition of the present invention can be added include, for example, various foods, for example, For example, there are drinks, gums, teas, vitamin complexes, and dietary supplements.
  • physiologically acceptable salt refers to a compound that is administered physiologically acceptable and administered to an organism, typically without causing an allergic or similar reaction, such as gastrointestinal disorders, dizziness, and the like. It means that it is commonly used that can exhibit the effect.
  • the food supplement additive may further include food supplement additives, including food supplement additives conventional in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like. .
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents for example, rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the antimicrobial food composition comprising the siarylactose of the present invention as an active ingredient is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, such as colorants and neutralizing agents (cheese, chocolate) Etc.), and the salts of pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. Others may contain pulp for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination.
  • the health supplement food in the present invention includes a health functional food and health food.
  • the functional food is the same term as food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, medical treatment has a high effect Means food.
  • the term "functionality” means obtaining useful effects for health purposes such as nutrient control or physiological action on the structure and function of the human body.
  • the food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding the raw materials and ingredients commonly added in the art.
  • the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
  • Another aspect of the present invention for achieving the above object provides an antimicrobial method comprising the step of treating a composition comprising a siary lactose as an active ingredient to the subject. More specifically, it provides an antimicrobial method against Klebsiella pneumoniae , comprising the step of treating the subject with a composition comprising cyaryllactose as an active ingredient.
  • the siaryl lactose, Krebssiella pneumoniae, antibacterial is as described above.
  • the term "individual” may refer to any animal, including humans, who are infected with or are likely to be infected by Krebsiella pneumoniae.
  • the animal may be a mammal such as, but not limited to, a human, a cow, a horse, a sheep, a pig, a goat, a camel, a antelope, a dog, a cat, and the like, which require treatment of similar symptoms.
  • the antimicrobial method of the present invention may include administering or applying the composition in a pharmaceutically effective amount to an individual infected with or at risk of being infected by Krebsiella pneumoniae.
  • the present invention encompasses administering a pharmaceutical composition comprising siarylactose in a pharmaceutically effective amount. It will be apparent to those skilled in the art that a suitable total daily usage may be determined by the practitioner within the scope of good medical judgment. It may also be administered once or in divided doses. However, for the purposes of the present invention, the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medicinal art, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or concurrent with the specific composition.
  • THP-1 human mononuclear cells
  • HL-60 neurotrophil cell line
  • A549 human lung epithelial cells
  • RPMI-1640 medium containing 10% FBS and antibiotics, ⁇ - mercaptoethanol, inactivated by heat.
  • Raw 264.7 rat macrophages were cultured in DMEM medium containing 10% FBS and antibiotics inactivated by heat, and the cells were cultured in a incubator supplied with 5% CO 2 at 37 °C.
  • 2,3-silylactose and 2,6-silylactose were obtained from Jinchem Co., Ltd., dissolved in distilled water and added to the cell culture medium.
  • THP-1 cells and Raw 264.7 cells were seeded in a 96 well plate by 5 ⁇ 10 3 seeding for one day, followed by 2,3-cyaryllactose and 2,6- Cyaryllactose was treated with 0.1 uM, 1 uM, 10 uM, 100 uM and 300 uM for 24 hours, respectively.
  • the viability of the cells was determined by placing Ez-Cytox reagent in each well and measuring the OD value using a reader.
  • THP-1 cells were seeded in 24 well plates by 2 x 10 5 and cultured per day, pretreated with 2,3-cyaryllactose for 3 hours, followed by LPS for 24 hours.
  • the culture supernatant of the cells was recovered, put into a 96 well plate coated with a capture antibody of CXCL8, and reacted at room temperature for 2 hours.
  • the TMB solution and the stop solution were added and fixed, and the degree of luminescence was measured using a reader.
  • the CXCL8 promoter region including STAT, AP-1, NF- ⁇ B binding sequences was amplified by PCR.
  • the obtained PCR product was cloned into a TA vector containing the same restriction enzyme site as the pGL4-Lucifearase vector.
  • the insert obtained from the TA vector was linked to the Kpn I-Xho I restriction site of the pGL4 vector, and the prepared plasmid vector was finally confirmed by sequencing.
  • A549 cells were seeded on a 24 well plate by 8 ⁇ 10 4 per well, and plasmid expression vectors were transfected into cell lines using Attractene reagents according to the manufacturer's protocol. Thereafter, 2,3-cyaryllactose was pretreated for 3 hours, followed by LPS for 24 hours. Lysis buffer was used to lyse cells, and luciferase reagent was added, and luciferase activity was measured using a luminometer.
  • Krybciella pneumoniae of siarylactose ( Klebsiella pneumoniae) Confirmation of phagocytosis promoting ability against bacteria
  • THP-1 cells were passaged and the number of 2 ⁇ 10 6 / ml was dispensed by 1 ml / well into 12 well-culture plates to prepare macrophage lines.
  • K. pneumoniae Inoculated into LB broth one day before the infection, and then incubated in 37 °C, shaking incubator for 16 to 20 hours.
  • Cultured K. pneumoniae was diluted to 20 x 1 PBS to 2 x 10 5 CFU to prepare for infection.
  • Prepared bacteria were adjusted to 10, 50 MOI (multiplicity of infection) to THP-1 cells in culture and mixed in the culture medium to determine the number of strains (internalization) by the macrophages into cells.
  • the phagocytosis activity of the cells was analyzed by adjusting the concentration of 2,3-silylactose and 2,6-silylactose to 100 nM.
  • K. pneumoniae was infected with THP-1 cells, which are cultured macrophage lines, and 0.5, 1, 2, and 3 hours later, K. pneumoniae, which was not phagocytized by macrophages, was removed by administering the antibiotic gentamicin (Gentamicin).
  • the efficacy of phagocytosis of K. pneumoniae was verified in the group administered with siarylactose at the same time. Macrophages were recovered and necrosis to determine the number of microorganisms present in the cells by phagocytosis, and the resulting colonies were measured through CFU using agar plates.
  • bacteria 1: 50 (MOI 50)
  • the antibiotic gentamicin was administered to remove bacteria that were not phagocytized by macrophages.
  • THP-1 cells treated with 2,3-cyaryllactose, 2,6-cyaryllactose and K. pneumoniae were recovered hourly (0.5, 1, 2, 4h), washed with PBS, and then paraformaldehyde (paraformaldehyde). ) Onto the slide.
  • TLR4 antibody (sc-13593, Santa Cruz Biotechnology, Dallas, TX, USA) was reacted to stain TLR4 present on the cell surface, followed by reaction with a FITC-conjugated 2ndary antibody, which was then subjected to confocal microscopy (a Zeiss LSM800 confocal). microscope, Carl Zeiss, Jena, Germany) to observe the cell surface protein.
  • THP-1 cells were seeded in 24 well plates by 2 x 10 and cultured per day, and pretreated with 2,3-cyaryllactose and 2,6-cyaryllactose for 3 hours, and then LPS was 30 minutes and 60 minutes. Treatments were taken for 120 minutes, 240 minutes. After washing the cells with PBS, the cells were fixed using paraformaldehyde without permeabilization to identify only Rac1 protein present on the cell surface. After blocking with 1% BSA, Rac1 antibody was added and allowed to react at room temperature for 1 hour. After reacting with Alexa fluor 594 bound secondary antibody and DAPI, the stained cells were observed under an optical microscope. (Rac1 localization).
  • the lysosomal activity was measured using the LYSO-ID Red Detection Kit. Specifically, THP-1 cells were seeded in 24 well plates by 2 x 10 and cultured daily, followed by pretreatment of 2,3-cyaryllactose and 2,6-cyaryllactose for 3 hours, followed by LPS 30 Treatments were taken for minutes, 60 minutes and 120 minutes. After washing the cells with the assay buffer, Lyso-tracker dye was added and reacted for 30 minutes at 37 degrees. After washing the cells once more with Assay buffer, the stained cells were observed under a light microscope.
  • THP-1 cells and Raw 264.7 cells were seeded by 5 x 10 3 in 96 well plates for 2,3-sialic acid. Lylactose and 2,6-cyaryllactose were treated with 0.1 uM, 1 uM, 10 uM, 100 uM and 300 uM for 24 hours, respectively, followed by WST assay as in Example 1-3.
  • THP-1 cells The expression of chemokines in THP-1 cells was confirmed by enzyme immunoassay (ELISA) as in Example 1-4.
  • ELISA enzyme immunoassay
  • THP-1 cells were pretreated with 2,3-cyaryllactose for 3 hours and treated with LPS for 24 hours to determine the expression levels of CXCL8 and TNF- ⁇ .
  • TNF- ⁇ showed no significant difference compared to the group treated with LPS alone, whereas CXCL8 increased expression three times as compared to the group treated with LPS only when treated with 2,3-cyaryllactose. (synergistic effects) was found (FIG. 2).
  • the CXCL8 reporter vector was prepared using a CXCL8 promoter region and luciferase expression gene including the binding sequences of STAT, AP-1, and NF- ⁇ B using gene recombination technology (FIG. 3A). . After injecting the prepared expression vector into A549 cells, 2,3-cyaryllactose was pretreated for 3 hours, and LPS was treated for 24 hours to induce expression, and then, luciferase activity was measured to compare and express expression levels. The activation of the promoter was measured.
  • Example 5 Krebsiella pneumoniae of carylactose ( Klebsiella pneumoniae) Confirmation of phagocytosis promoting ability against bacteria
  • Example 1-7 By the method described in Example 1-7, the phagocytosis-promoting ability of the cyclyl lactose against Klebsiella pneumoniae bacteria was confirmed.
  • the number of bacteria present in the cells was significantly reduced through the activity of the macrophages after 4 hours after the bacteria in the cells were removed.
  • Example 6 Confirmation of phagocytosis promoting ability against Staphylococcus aureus, Streptococcus pseudopneumonia
  • Example 1-8 By the method described in Example 1-8, it was confirmed whether or not other bacteria except Klebsiella pneumoniae has the same antimicrobial activity.
  • Example 7 K. pneumoniae Validation of phagocytosis through endocytosis of Toll like receptor4
  • THP-1 cells treated with LPS recognize LPS through the TLR4 receptor and endocytosis occurs into the cell.
  • TLR4 One hour after LPS treatment, most of the receptor, TLR4, enters the cell and after four hours returns to the cell surface (endocytosis-exocytosis cycle).
  • Example 1-9 phagocytosis activity was confirmed through endocytosis verification of Toll like receptor4.
  • Example 8 Confirmation of assembly and lysosomal activity of RAC, a free radical (ROS) synthase, on the cell surface
  • Example 1-10 Specific mechanism of action was confirmed by the method of Example 1-10 on the antimicrobial activity of cyaryllactose against the Krebsiella pneumoniae strain.
  • siaryl lactose promotes the phagocytosis of macrophages against Krebs.
  • Neumoniae strains and confirms that the material exhibits excellent antimicrobial activity by rapidly increasing the content of free radicals and lysosomal activity in macrophages.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne: une composition antibactérienne pour Klebsiella pneumoniae, contenant du sialyllactose en tant que principe actif; et similaire.
PCT/KR2018/002390 2017-02-27 2018-02-27 Composition antibacterienne contenant du sialyllactose en tant que principe actif Ceased WO2018155995A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0025431 2017-02-27
KR20170025431 2017-02-27

Publications (1)

Publication Number Publication Date
WO2018155995A1 true WO2018155995A1 (fr) 2018-08-30

Family

ID=63252820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/002390 Ceased WO2018155995A1 (fr) 2017-02-27 2018-02-27 Composition antibacterienne contenant du sialyllactose en tant que principe actif

Country Status (2)

Country Link
KR (1) KR102019364B1 (fr)
WO (1) WO2018155995A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491289A (zh) * 2020-04-03 2021-10-12 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖
CN114568697A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 可调控肠道巨噬细胞并激活免疫的人乳寡糖及其应用
CN114568528A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 一种可调控肠道免疫的婴幼儿配方食品及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102019676B1 (ko) * 2018-02-02 2019-09-11 상지대학교산학협력단 시아릴락토오스(Sialyllactose)를 포함하는 전립선 비대 질환 예방 또는 치료용 조성물
KR102116416B1 (ko) 2019-01-09 2020-05-29 백승배 6'-시알릴락토오스 및 다이드제인으로 이루어진 암 예방 또는 치료용 조성물.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020087226A (ko) * 2001-05-14 2002-11-22 (주)바이오케어 폐렴균에 대한 항균제
US20120214759A1 (en) * 2009-05-14 2012-08-23 Achaogen, Inc. Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
US20130035481A1 (en) * 2010-02-19 2013-02-07 Glycom A/S Production of 6'-o-sialyllactose and intermediates
KR20140093525A (ko) * 2013-01-18 2014-07-28 경희대학교 산학협력단 아디프 산을 유효성분으로 포함하는 폐렴 간균에 대한 항균용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507483A (zh) 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
CN103566371B (zh) 2012-08-01 2015-09-09 南京神奇科技开发有限公司 抗微生物的物理方法
US10105681B2 (en) 2013-03-14 2018-10-23 Ran Biotechnologies, Inc. Methods and materials for microorganism capture
KR101773066B1 (ko) 2017-01-23 2017-08-30 아주대학교산학협력단 3'-시알릴락토오스 또는 이의 유도체를 유효성분으로 함유하는 퇴행성관절염의 예방 또는 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020087226A (ko) * 2001-05-14 2002-11-22 (주)바이오케어 폐렴균에 대한 항균제
US20120214759A1 (en) * 2009-05-14 2012-08-23 Achaogen, Inc. Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds
US20130035481A1 (en) * 2010-02-19 2013-02-07 Glycom A/S Production of 6'-o-sialyllactose and intermediates
KR20140093525A (ko) * 2013-01-18 2014-07-28 경희대학교 산학협력단 아디프 산을 유효성분으로 포함하는 폐렴 간균에 대한 항균용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, CHEN-HSIANG: "Sialic acid involved in hypermucoviscosity phenotype of Klebsiella pneumoniae and associated with resistance to neutrophil phagocytosis", VIRULENCE, vol. 5, no. 6, 2014, pages 673 - 679, XP055535768 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491289A (zh) * 2020-04-03 2021-10-12 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖
EP4129302A4 (fr) * 2020-04-03 2024-04-17 Inner Mongolia Yili Industrial Group Co., Ltd. Oligosaccharides du lait maternel pour l'amélioration de la résistance d'un organisme contre une infection au staphylococcus aureus
CN114568697A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 可调控肠道巨噬细胞并激活免疫的人乳寡糖及其应用
CN114568528A (zh) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 一种可调控肠道免疫的婴幼儿配方食品及其应用

Also Published As

Publication number Publication date
KR102019364B1 (ko) 2019-09-06
KR20180099543A (ko) 2018-09-05

Similar Documents

Publication Publication Date Title
WO2018155995A1 (fr) Composition antibacterienne contenant du sialyllactose en tant que principe actif
WO2022114728A2 (fr) Composition comprenant un inhibiteur de shmt ou un inhibiteur de mthfr pour traiter une infection bactérienne
WO2019088379A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2018092955A1 (fr) Analogue peptidique antimicrobien dérivé d'haliotis discus et composition pharmaceutique antimicrobienne le contenant
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
EP4698198A1 (fr) Composition comprenant akkermansia sp.
WO2019231220A1 (fr) Utilisation d'un composé thiophène 2,3,5-substitué pour prévenir, atténuer ou traiter des cancers du sein
KR20220071901A (ko) Shmt 억제제 또는 mthfr 억제제를 포함하는 박테리아 감염 치료용 조성물
WO2020106048A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie neurodégénérative
WO2025263982A1 (fr) Akkermansia biwaensis pour la prévention ou le traitement de troubles métaboliques et utilisation associée
WO2019172666A1 (fr) Nouveau peptide antimicrobien dérivé du peptide ll37 et utilisation associée
WO2017074031A1 (fr) Composition immunostimulante contenant de l'arabinoxylane dérivée du maïs et des sous-produits de traitement du maïs
WO2016093641A1 (fr) Composition antibactérienne contenant une protéine adk utilisée comme principe actif, ou composition pour la prévention ou le traitement d'une septicémie
WO2023068855A1 (fr) Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse
WO2023014048A1 (fr) Souche de bifidobactérium ou pediococcus sp. et les vésicules qui en sont dérivées, et leurs utilisations anti-inflammatoires et antibactériennes
WO2026010473A1 (fr) Composition pour la prévention ou le traitement de l'arthrite comprenant une souche de pediococcus acidilactici sy23
WO2022039514A1 (fr) Composition pour le traitement de maladies cérébrales comprenant lactobacillus sakei ou des vésicules extracellulaires dérivées de celui-ci en tant que principe actif
WO2022039561A1 (fr) Composition pour le traitement ou la prévention d'une infection par clostridium difficile
WO2024196187A1 (fr) Nouvelle souche latilactobacillus sakei cnsc001wb à fonction immunomodulatrice et son utilisation
WO2016032250A1 (fr) Composition pharmaceutique contenant un extrait de portulaca grandiflora hook. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
WO2014182078A1 (fr) Composition pour la régulation de l'activité immunologique dans les intestins et son utilisation
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
WO2024038980A1 (fr) Souche de lactobacillus plantarum ku15120 ou son utilisation
WO2023014054A1 (fr) Souches blautia sp., leuconostoc sp. ou ruminococcus sp. et réticulum endoplasmique dérivé de celles-ci, et leurs utilisations anti-inflammatoires et antibactériennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756748

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756748

Country of ref document: EP

Kind code of ref document: A1